MARKET OVERVIEW- UNITED STATES ANTIEPILEPTIC DRUGS MARKET
The tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults is also known as epilepsy. Epilepsy can be caused by various conditions that affect a person’s brain. Commonly, the reason is unknown. Some causes include brain tumour, traumatic brain injury or head injury, brain stroke, central nervous system infection.
Antiepileptic drugs (AEDs) are those that reduce the frequency and/or severity of seizures in people with epilepsy. The older term, anticonvulsant drug, is still occasionally used as a synonym for AED, but is less accurate because many seizures do not involve convulsive movements. An antiepileptic is a type of drug that is utilized to prevent or treat seizures or convulsions by controlling abnormal electrical activity in the brain. The choice of the antiepileptic drug depends on the patient's age, the type of seizures to be treated, and the severity of the seizures. The primary mechanism of the antiepileptic drugs is to block voltage-gated sodium channels during rapid rates of neuronal discharge.
MARKET DRIVERS
Rising awareness about the antiepileptic drugs in the market, increasing prevalence of epilepsy and seizure disorders are the primary factors that are responsible for the United States Antiepileptic drugs market growth over the foreseen period in the US. In the year 2015, approximately 3 million adult Americans reported having active epilepsy, according to the National Health Interview Surveys (NHISs). The FDA has approved 24 antiepileptic drugs for use in epilepsy in the United States.
In addition, the region's steady growth is anticipated to be significantly aided by the presence of established market players and an advanced healthcare ecosystem over the forecast period. As a result, it is anticipated that the antiepileptic drug market will expand gradually over the foreseen period.
MARKET OPPORTUNITY
In order to improve patients symptoms and their quality of life, as well as that of the caregivers, there is a great deal of responsibility placed on the R&D of novel pharmacological and non-pharmacological therapies with a focused approach. This is expected to provide ample new growth opportunities in the market during the forecast period. According to analysis from the NHIS, an estimated 2.6 million (1.1%) adults in the United States self-reported having active epilepsy each year. 67% of whom had seen a neurologist or an epilepsy specialist, and 90% of whom reported taking epilepsy medication. In addition, an increase in the incidence of serious injuries while impaired by alcohol or drugs, an increase in stress and depression, and the desire for a successful life are the factors that will increase the market's growth opportunity in the future.
MARKET RESTRAINTS
The antiepileptic drug market is growing in the US despite the increasing prevalence of epilepsy, seizures, and other chronic conditions in developing nations. There are major factors that restrain the market's growth, including cognitive adverse effects of drugs. United States Antiepileptic drug market's expansion was also hampered by the adverse effects of antiepileptic medications on liver damage, dizziness and drowsiness and skin conditions.
MARKET GROWTH CHALLENGES
A key challenge that may affect the growth of the market is the number of health issues associated with the drugs. Epilepsy is perhaps one of the oldest recorded medical conditions in history. Some of the antiepileptic drugs on the market today are ineffective, and their negative properties limit their use and make patient management challenging. Antiepileptic medications can only alleviate symptoms because they suppress seizures but cannot cure epileptogenesis. The long-term use of antiepileptic drugs is limited due to their adverse effects, withdrawal side effects, drug-drug interactions, and economic burden. These are the major challenges for the United States Antiepileptic market's growth over the foreseen period.
CUMULATIVE GROWTH ANALYSIS
The report provides an in-depth analysis of United States Antiepileptic drugs market, market size, and compound annual growth rate (CAGR) for the forecast period of 2023-2029, considering 2022 as the base year. A rise in demand for antiepileptic drugs in various applications is anticipated to stimulate the growth of the market and due to this factor, the market is expected to witness growth at a specific CAGR from 2023-2029.
UNITED STATES ANTIEPILEPTIC DRUGS MARKET SEGMENTAL OVERVIEW
The United States Antiepileptic drugs market comprises of different market segments like, drug type, form, administered route, distribution channel.
UNITED STATES ANTIEPILEPTIC DRUGS MARKET BY SIZE
By drug type, the United States Antiepileptic drugs market includes key segments like
- First Generation
- Second Generation
- Third Generation
The second-generation segment is anticipated to dominate the US market over the projected time period. This is due to their effectiveness and good tolerability profile. Over the past 15 years, nine second-generation antiepileptics have been approved for use in epilepsy in the United States. Vimpat, lyrica, keppra aptiom, and banzelfycompa are examples of second-generation antiepileptic drugs. Gabapentin and Felbamate were the first two second-generation antiepileptic drugs to be approved in the US. The first-generation segment is projected to experience significant growth over the forecast period, including mysoline, zarontin, carbatrol, topamax, and luminal.
UNITED STATES ANTIEPILEPTIC DRUGS MARKET BY FORM
By form, the United States Antiepileptic drugs market includes key segments like
On the basis of form the United States Antiepileptic drugs market includes key segments like dry and liquid. Antiepileptic drugs (AEDs) are usually the first choice of treatment. When antiepileptic drugs are administered orally, the majority of drugs are completely or nearly completely absorbed. Most often, administration of antiepileptic drugs with food slows absorption and can help avert peak dose-related side effects.
UNITED STATES ANTIEPILEPTIC DRUGS MARKET BY ADMINISTERED ROUTE
By administered route, the United States Antiepileptic drugs market includes key segments like
- Oral
- Vein Injections/Intravenous
On the basis of administered route, the United States Antiepileptic drugs market includes key segments such as oral, and vein injections/intravenous. The oral segment is expected to hold the major shares of the United States Antiepileptic market over the forecast period. Oral administration of the medications is frequently used for the long-term treatment of epilepsy due to its safety, patient compliance, ease of administration, pain relief, and adaptability to accommodate a variety of medications. Vein injections or intravenous routes are used alone or in combination with other medications to treat partial-onset seizures in adults, children, and new-borns under one month of age who are unable to take oral medications.
UNITED STATES ANTIEPILEPTIC DRUGS MARKET BY DISTRIBUTION CHANNEL
By distribution channel, the United States Antiepileptic drugs market includes key segments like
- Offline Channels
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Platforms
On the basis of distribution channel, the United States Antiepileptic drugs market includes key segments like offline channels, hospital pharmacies, retail pharmacies, drug stores, online platforms. The offline segment is expected to hold the major shares of the United States Antiepileptic market over the forecast period. The growth of the segment is to be attributed to the full-fledged and all-encompassing nature of offline facilities.
COVID-19 IMPACT ANALYSIS ON UNITED STATES ANTIEPILEPTIC DRUGS MARKET
The COVID-19 outbreak has had a significant impact on the market's growth as several neurology activities, including medical training and research, were disrupted due to the pandemic. People with novel coronavirus disease (SARS-CoV2) may have encephalitis, multi-organ failure, hypoxia, meningitis, and severe metabolic and electrolyte imbalance. As a result, it is anticipated that these patients will experience clinical or subclinical acute symptomatic seizures, particularly when they are admitted to the hospital. It was found that of COVID-19 patients experienced at least one seizure during treatment, and 25 % of COVID-19 patients had central nervous system (CNS) manifestations.
In addition, the growth of the United States Antiepileptic market is expected to expand in the coming years due to the increasing awareness levels about epilepsy and strategic alliances.
COMPETITIVE LANDSCAPE ANALYSIS
The competitive landscape analysis of United States Antiepileptic drugs market is primarily focused on expanding the US growth of antiepileptic drugs industry with new product innovation, business expansion, increasing presence of range of manufacturer operating in antiepileptic drugs sector has led the growing demand for the market. Besides, the market offers range of products in different application to fulfil the required demand of consumer which is further contributing healthy growth in the market.
The key players studied in market are
- Abbott Laboratories (US)
- Johnson & Johnson (US)
- Pfizer Inc (US)
- Sunovion Pharmaceuticals (US)
- Cephalon Inc (US)
- Cadwell Industries Inc (US)
- Boston Scientific Corporation (US)
- Novartis AG (US)
- SK Life Science, Inc. (US)
- Sorrento Therapeutics (US)
- Upsher-Smith (US)
- Eli Lilly & Company (US)
- Zydus Pharmaceuticals (USA) Inc (US)
- Appco Pharma LLC (US)
RECENT DEVELOPMENT:
January 2023: Zydus Pharmaceuticals (USA) Inc. has announced the launch launched topiramate extended-release capsules in the US market with strengths of 25 mg, 50 mg, and 100 mg.
September 2022: Upsher-Smith Laboratories, LLC (Upsher-Smith) announced their partnership to add their development strengths to the company's core competencies and expand their product portfolio to accelerate growth in the U.S. with the addition of a near-term generic product opportunity.
